SCHEMBL12484646

SCHEMBL12484646

Cc1cccc(CCNC(=O)c2c[nH]c(CN)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
POLB P06746 1/20 0.48
MMP13 P45452 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CNR1 P21554 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 3/20 0.43
MAPT P10636 3/20 0.43
HIF1A Q16665 1/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173517 0.86 HIF1A (0.54) NPC1RAB9ACNR1SMN1; SMN2MAPT
SCHEMBL18773973 0.72 NPC1 (0.86) NPC1RAB9APOLBHDAC3HDAC1
SCHEMBL11895626 0.71 NPC1 (0.65) NPC1RAB9APOLBHDAC3HDAC1
SCHEMBL3824389 0.71 HDAC3 (0.69) NPC1RAB9APOLBHDAC3HDAC1
SCHEMBL28699553 0.71 RAB9A (0.83) NPC1RAB9APOLBHDAC3HDAC1
SCHEMBL2172312 0.70 KDM4E (0.48) NPC1RAB9ACNR1SMN1; SMN2MAPT
SCHEMBL10112805 0.70 HDAC3 (0.59) NPC1RAB9APOLBHDAC3HDAC1
SCHEMBL16628733 0.68 ADORA2A (0.59) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL30057191 0.68 ALDH1A1 (0.57) NPC1RAB9APOLBHDAC3HDAC1
SCHEMBL18875032 0.68 ALDH1A1 (0.57) NPC1RAB9APOLBHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 NPC1 1296/4885RAB9A 2862/4885POLB 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.